Loading the player...
The Acutely Medically Ill Patient in the Hospital
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
In this case-based program, Dr. Michael Gibson discusses treatment of a hospitalized patient with VTE.

This transcript is software driven, please understand there may be errors.  Should any inaccuracies or omissions be found, please notify transcripts@MedEdOTG.com for correction.

Hi, I'm Dr. Michael Gibson from Harvard Medical School. Today we're talking about a patient with VTE. This is a 67 year old female patient. She had a history of COPD. She was diagnosed with a severe respiratory infection. She was admitted to the hospital yesterday and was severely immobilized.

Now, she's expected to stay in the hospital for several days. So, here's the question, in general, what's the proximate risk of VTE developing during hospitalization? Is it 0%? .5%? 1.4% or 6.2%?

When the answer is shown here, the risk is 1.4% or answer C. Acutely ill hospitalized patients are at an increased risk of VTE during the hospitalization period. As we'll see in other segments, that risk extends beyond hospitalization at well.

So, the next question is this: How can the risk of VTE be reduced in this patient? The answer is this: Administering a 160 milligram loading dose of betrixaban followed by a maintenance dose of 80 milligrams for the next 35 to 42 days has recently been shown in the APEX study to reduce the risk of VTE compared to enoxaparin for the standard duration of hospitalization.

So to summarize, this was a patient who had COPD and an infection who was immobilized. The numbers indicate that these patients are at a high risk of VTE. This risk of VTE can be reduced by a new drug, betrixaban, given orally for the next 35 to 42 days as compared to the enoxaparin.

I hope you've enjoyed this segment.